A Study of KMV002 in Patients With mAPMR Prostate Cancer

StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a first-in-human (FIH) open-label, multicenter, dose-escalation and dose-expansion Phase I study of KMV002 in metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer patients. This study consists of two parts: dose escalation (Part 1) and dose expansion (Part 2). Following a screening period, eligible mAPMR patients will be enrolled to receive their assigned regimen of KMV002 (a combination of SN3001C and CpG ODN adjuvant). KMV002 will be given as either a 5-dose or 6-dose regimen.
Trial Details
NCT Number NCT07866300
Lead Sponsor Chimivac INC
Collaborators: Chimigen Biomedical (Chengdu) Co., Ltd.
Conditions
(from sponsor)		 Prostate Cancer Metastatic Castration-Resistant
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov